Drug intelligence / Profile preview

colistin + tobramycin

Development stage
Phase 3
Lead developer
University Medical Center Utrecht
Modality
Small Molecules
Administration
Oral
01

Overview

Pre-OP is an oral, non-absorbable antibiotic combination solution containing colistin sulphate (20 mg/mL) and tobramycin (16 mg/mL). Developed by Universitair Medisch Centrum Utrecht (UMC Utrecht), it is specifically designed for the prevention of surgical site infections (SSIs) and postoperative wound infections in patients undergoing elective colorectal surgery. The combination functions as a selective decontamination of the digestive tract (SDD) regimen, targeting gram-negative intestinal bacteria. Colistin, a polymyxin antibiotic, acts by binding to lipopolysaccharides and phospholipids in the outer cell membrane of gram-negative bacteria, leading to membrane disruption. Tobramycin, an aminoglycoside antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Because neither active ingredient is significantly absorbed from the gastrointestinal tract when administered orally, the drug achieves high local concentrations in the gut with minimal systemic exposure, resulting in a favorable safety profile.

Brand names
Pre-OP
Other names
colistin sulphate + tobramycincolistin and tobramycin
02

Targets

16S ribosomal RNA aminoacyl-tRNA site (16S rRNA A-site)Lipid A phosphate (Lipid A phosphate groups)Bacterial Ribosome

Beyond the preview

Go deeper on colistin + tobramycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on colistin + tobramycin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call